|
2025 Journal Article Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Sidiqi, M Hasib, Wellard, Cameron, Ashrafi, Elham, Harrison, Simon, Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Ho, Phoebe Joy, King, Tracy, Mollee, Peter, Quach, Hang, Rajagopal, Rajeev, McQuilten, Zoe, Wood, Erica, Rosengarten, Brian and Spencer, Andrew (2025). Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. Blood, 146 (Supplement 1), 2221-2221. doi: 10.1182/blood-2025-2221 |
|
2025 Journal Article Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)Lim, Sueh-Li, Reynolds, John, Pemberton, Lucy, Wright, Tricia, Lee, Sophie, Mollee, Peter, Shetty, Anita C., Kim, Yu Jin, Helen, Weston, Nina, Byard, Le, Khoa, McQuilten, Zoe, Quach, Hang and Spencer, Andrew (2025). Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22). Blood, 146 (Supplement 1), 5842-5842. doi: 10.1182/blood-2025-5842 |
|
2025 Journal Article Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosisChakraborty, Rajshekhar, Kastritis, Efstathios, Huart, Antoine, Jaccard, Arnaud, Landau, Heather, Iida, Shinsuke, Motorna, Olga, Mollee, Peter, Ishida, Tadao, Kawano, Yawara, Bhutani, Manisha, D'Souza, Anita, Cowan, Andrew, Hoffman, James, Talati, Chetasi, Rosenberg, Tanya, La Motte-Mohs, Ross, Wang, Fan, Hoffman, David, Fei, Mingwei, Arriola, Emma, Yu, Jovian, Kumar, Shaji, Dispenzieri, Angela, Palladini, Giovanni and Sanchorawala, Vaishali (2025). Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis. Blood, 146 (Supplement 1), 692-692. doi: 10.1182/blood-2025-692 |
|
2025 Journal Article Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Rees, Matthew, Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M Hasib, Wong Doo, Nicole, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William, McCaughan, Georgia, Eek, Richard, Lenton, Douglas, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter and Quach, Hang (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). Blood, 146 (Supplement 1), 4039-4039. doi: 10.1182/blood-2025-4039 |
|
2025 Journal Article A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of AmyloidosisSanchorawala, Vaishali, Wechalekar, Ashutosh, Mollee, Peter, Sekijima, Yoshiki, Maurer, Mathew S., Leung, Nelson, Schönland, Stefan O. and Kumar, Shaji (2025). A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid, 32 (4), 1-6. doi: 10.1080/13506129.2025.2570096 |
|
2025 Journal Article Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosisRanjit Anderson, Nirija, Dorbala, Sharmila and Mollee, Peter (2025). Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis. Blood Journal, 146 (10) blood.2024026386, 1157-1162. doi: 10.1182/blood.2024026386 |
|
2025 Journal Article Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomesPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Wang, George, Gupta-Werner, Niodita, Kaila, Shuchita, Pei, Huiling, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2025). Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes. European Journal of Haematology, 114 (5), 883-889. doi: 10.1111/ejh.14392 |
|
2025 Journal Article Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patientsLim, Kenneth J C, Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, P. Joy, Janowski, Wojt, Kim, Kihyun, McCaughan, Georgia, Dun, Karen, McQuilten, Zoe, Chen, Fiona and Quach, Hang (2025). Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patients. Clinical Lymphoma Myeloma and Leukemia, 25 (4), 243-248. doi: 10.1016/j.clml.2024.11.002 |
|
2025 Journal Article Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic reviewSia, Aaron, Chopra, Sakshi, Ling, Victoria Y., Fletcher, James, Hubbard, Ruth Eleanor, Mollee, Peter, Gordon, Emily, Reid, Natasha and Hanjani, Leila Shafiee (2025). Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic review. Journal of Geriatric Oncology, 16 (3) 102196, 102196. doi: 10.1016/j.jgo.2025.102196 |
|
2025 Journal Article Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trialHapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2025). Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002 |
|
2025 Journal Article A Comparison of Peripherally Inserted Central Catheter MaterialsUllman, Amanda J., August, Deanne, Kleidon, Tricia M., Walker, Rachel M., Marsh, Nicole, Bulmer, Andrew C., Pearch, Ben, Runnegar, Naomi, Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Gibson, Victoria, Royle, Ruth, Southam, Katrina, Byrnes, Joshua, Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M., Harris, Patrick N. A. and Ware, Robert S. (2025). A Comparison of Peripherally Inserted Central Catheter Materials. New England Journal of Medicine, 392 (2), 161-172. doi: 10.1056/nejmoa2406815 |
|
2024 Journal Article Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryIrving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS One, 19 (8 August) e0308812, e0308812. doi: 10.1371/journal.pone.0308812 |
|
2024 Journal Article Variation in immunoglobulin use and impact on survival in myelomaChai, Khai Li, Wellard, Cameron, Thao, LTP, Aoki, Naomi, Moore, Elizabeth M, Augustson, Bradley M, Bapat, Akshay, Blacklock, Hilary, Chng, Wee J, Cooke, Rachel, Forsyth, Cecily J, Goh, Yeow‐Tee, Hamad, Nada, Harrison, Simon J, Ho, P Joy, Hocking, Jay, Kerridge, Ian, Kim, Jin Seok, Kim, Kihyun, King, Tracy, McCaughan, Georgia J, Mollee, Peter, Morrissey, C Orla, Murphy, Nick, Quach, Hang, Tan, Xuan Ni, Tso, Allison CY, Wong, Kimberly SQ, Yoon, Sung‐Soo ... McQuilten, Zoe K (2024). Variation in immunoglobulin use and impact on survival in myeloma. eJHaem, 5 (4), 690-697. doi: 10.1002/jha2.938 |
|
2024 Journal Article Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapseHo, P. Joy, Spencer, Andrew, Mollee, Peter, Bryant, Christian E., Enjeti, Anoop K., Horvath, Noemi, Butcher, Belinda E., Trotman, Judith, Gibbs, Simon and Joshua, Douglas E. (2024). Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse. Clinical Lymphoma Myeloma and Leukemia, 24 (8), 543-552. doi: 10.1016/j.clml.2024.04.001 |
|
2024 Journal Article Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon, Lee, Sophie, Lee, Edwin, Taylor, Kerry, Cochrane, Tara, Wallington-Gates, Craig, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian, Weston, Helen, Ho, P. Joy, Leahy, Michael F, Horvath, Noemi and Spencer, Andrew (2024). Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16). Blood Advances, 8 (14), 3721-3730. doi: 10.1182/bloodadvances.2023012539 |
|
2024 Journal Article The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)Ho, P. Joy, Moore, Elizabeth, Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrrison, Simon J., MacDonald, Emma‐Jane, McQuilten, Zoe K., Wood, Erica M., Mollee, Peter and Spencer, Andrew (2024). The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). British Journal of Haematology, 205 (4), 1337-1345. doi: 10.1111/bjh.19624 |
|
2024 Journal Article Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 studyNinkovic, Slavisa, Harrison, Simon J, Lee, Je-Jung, Murphy, Nick, Lee, Jae Hoon, Estell, Jane, Chen, Vivien M, Horvath, Noemi, Kim, Kihuyn, Eek, Richard, Augustson, Bradley, Bang, Soo-Mee, Huang, Shang-Yi, Rajagopal, Rajeev, Szabo, Ferenc, Engeler, Daniel, Butcher, Belinda E, Mollee, Peter, Durie, Brian, Chng, Wee Joo and Quach, Hang (2024). Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study. Haematologica, 109 (7), 2229-2238. doi: 10.3324/haematol.2023.284238 |
|
2024 Journal Article 2024 Australia–New Zealand Expert Consensus Statement on Cardiac AmyloidosisBart, Nicole K., Fatkin, Diane, Gunton, James, Hare, James L., Korczyk, Dariusz, Kwok, Fiona, Lam, Kaitlyn, Russell, David, Sidiqi, Hasib, Sutton, Tim, Gibbs, Simon D.J., Mollee, Peter and Thomas, Liza (2024). 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Heart, Lung and Circulation, 33 (4), 420-442. doi: 10.1016/j.hlc.2023.11.027 |
|
2024 Journal Article Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?Ranjit Anderson, Nirija, Korczyk, Dariusz and Mollee, Peter (2024). Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?. Expert Review of Hematology, 17 (9), 567-579. doi: 10.1080/17474086.2024.2388184 |
|
2023 Journal Article Screening for and diagnosis of monoclonal gammopathyChong, Yuh Ping, Lim, Say Min, Loh, Tze Ping, Mollee, Peter, Wijeratne, Nilika and Choy, Kay Weng (2023). Screening for and diagnosis of monoclonal gammopathy. Journal of Clinical Pathology, 76 (11), 727-733. doi: 10.1136/jcp-2023-208774 |
